Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
The circulating anti-RCC cytotoxic antibodies of eighteen RCC patients, preoperatively, and one inoperable case were studied by 51Cr release CDC and ADCC assays, using the cultured human RCC cell line, OUR-10. Circulating cytotoxic anti-RCC antibodies were detected in eight patients as CDC antibodies. The patients with a low pathological grade had a significantly higher percentage (P less than 0.05) of positive antibody responses.
D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology; D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000920:Antibody-Dependent Cell Cytotoxicity; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
D000912:Antibodies, Neoplasm; D003165:Complement System Proteins